EGFR and cancer: Patients with EGFR-mutant NSCLC are more likely to develop BM (70%) than patients with a WT (wild type) EGFR (38%).29 Although, EGFR-mutant NSCLC had longer OS than EGFR WT, likely secondary to the availability and efficacy of EGFR-targeted therapy, the increased incidence of BM is not entirely explained by this difference in survival.32 Notably, studies show that EGFR-mutant NSCLC has a higher incidence of BM at the time of diagnosis, suggesting an inherent propensity for BM in these cancers compared to WT.33